Video
Dr. Goldberg explains disparities in shared decision-making for prostate cancer screening
Author(s):
“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
Video Player is loading.
Hanan Goldberg, MD, MSc, discusses the sociodemographic disparities found in his recent study on shared decision-making for prostate cancer screening, which was presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Goldberg is an assistant professor at SUNY Upstate Medical University in Syracuse, New York.
Related Videos
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos discusses PSA kinetics in mHSPC
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Related Content
